Client news

A&O Shearman supports GSK on its license agreement with Frontier Biotechnologies Inc.

A&O Shearman supports GSK on its license agreement with Frontier Biotechnologies Inc.
Published Date
Feb 23 2026
Related people
Image of Nigel Parker
Nigel ParkerPartner, London
Image of Jill Ge
Jill GePartner, Shanghai
Image of Megan McMellon
Megan McMellonSenior Associate, London
Image of Millie Fantham
Millie FanthamAssociate, London
A&O Shearman has advised global biopharma GSK on its licensing agreement with Frontier Biotechnologies Inc., a research-based, commercial-stage, publicly-traded biopharma company dedicated to the discovery, development, manufacture, and commercialization of innovative medicines, under which Frontier will exclusively license two of its small interfering RNA pipeline products to GSK on a worldwide basis.

Frontier will complete initial development activities for the two products, comprising a phase 1 clinical trial in the PRC and various IND-enabling activities, before GSK assumes control of development, manufacture, and commercialization.

The A&O Shearman team was led by IP transactions partner Nigel Parker and senior associate Megan McMellon, supported by IP transactions associate Millie Fantham. Jill Ge, David Zhang and Bree Chen provided valuable PRC support.

“We were proud to support GSK on a transaction that reflects our team’s deep expertise in complex, cross-border life sciences partnerships.”

Related capabilities